Abstract
The demographics of esophageal cancer in Australia reflect those of other Western countries [1] with a rising incidence in adenocarcinoma of the lower esophagus and esophago-gastric junction. However, in Western countries we still see patients with squamous cell carcinoma of the thoracic and cervical esophagus. The other change over the last 20 years has been an evolution of the use of the combination of chemotherapy with radiation therapy in the management of patients with esophageal cancer. Traditionally, resection was the definitive curative therapy, with radiation therapy used for patients who were not medically fit or who refused resection. However, the combination of chemoradiation therapy without resection was shown to offer a greater potential for cure for patients with squamous cell carcinoma, when compared with radiation therapy alone [2]. Thus, the recent trend has been to use concurrent chemoradiation therapy as definitive treatment or as neoadjuvant therapy for those patients having a resection [3, 4]. Recently, two randomized studies have supported the use of definitive chemoradiation therapy instead of esophageal resection in medically fit patients with squamous cell carcinoma [5, 6]. The role for definitive chemoradiation therapy in patients with adenocarcinoma of the esophagus is not clear, as most trials have had a predominance of squamous cell carcinoma. At this time the gold standard is still resection for locally advanced disease with the use of preoperative chemotherapy or chemoradiation therapy, given the survival benefits shown in meta-analyses [7]. There are some data to suggest that neoadjuvant chemoradiation therapy results in downstaging and improves resectability [8, 9].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pohl H, Welch G. The role of over-diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.
Herskovic A, Martz K, Al-Sarraf MV, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl J Med. 1992;326:1593–8.
Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer. 2002;38:300–13.
Geh JI, Crellen AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88: 338–56.
Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.
Chui P, Chan A, Leung S, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous oesophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg. 2005;9:794–802.
Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal cancer: a meta-analysis. Lancet Oncol. 2007;8:226–34.
Burmeister B, Smithers BM, Thomas J, et al. A randomized phase II trial comparing pre-operative chemotherapy with pre-operative chemoradiation therapy for localised carcinoma of the oesophagus. Eur J Cancer 2011;47:354–60.
Stahl M, Walz MK, Stuschke M, et al. Phase II comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.
Baxi SN, Burmeister B, Harvey JA, et al. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery; retrospective review. J Med Imaging Radiat Oncol. 2008;52:1–5.
Smithers BM, Cullinan M, Thomas JM, et al. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy. Dis Esophagus. 2007;20:471–7.
Burmeister BH, Smithers BM, Gebski V, et al. A randomised phase III study comparing surgery alone with chemoradiation therapy followed by surgery for resectable carcinoma of the oesophagus: an intergroup study of the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Lancet Oncol. 2005;6:659–68.
Conroy T, Marchal F, Blazeby JM. Quality of life in patients with oesophageal and gastric cancer: an overview. Oncology. 2006;70:391–402.
Hallas CN, Patel N, Oo A, et al. Five-year survival following oesophageal cancer resection: psychological functioning and quality of life. Psychol Health Med. 2001;6:684–94.
National Comprehensive Cancer Network. Practice Guidelines in Oncology: Esophageal Cancer: Version 1. Available: http://www.nccn.org (2009).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this chapter
Cite this chapter
Smithers, B.M., Thomas, J.M., Burmeister, B.H. (2013). Esophagus Carcinoma Surveillance Counterpoint: Australia. In: Johnson, F., et al. Patient Surveillance After Cancer Treatment. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-969-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-60327-969-7_17
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-968-0
Online ISBN: 978-1-60327-969-7
eBook Packages: MedicineMedicine (R0)